Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline's financial performance for the 12-month period ending December 2025 reflects significant growth, with sales revenue rising 11.47% year-over-year from $25.51 billion to $28.43 billion and an increase in return on capital from 7.22% to 7.44%. The company achieved $2.4 billion in new customer signings in 2025, driven by strong demand for its Medline-branded products and supply chain solutions, which now account for nearly half of its revenue and over 80% of its sales segment. Projections indicate further revenue growth of 257.98% in the next twelve months, reflecting the positive momentum and robust market positioning supported by Medline's extensive distribution network and manufacturing capabilities.

Bears say

Medline's financial outlook is impaired by a significant 220.79% year-over-year decline in Economic Profit, shifting from a gain of $345.1 million to a loss of $416.9 million, primarily due to equity cost measurements following its IPO. Additionally, the company faced a 12.66% decrease in Net Operating Profit After Tax (NOPAT), falling from $2.45 billion to $2.14 billion, along with a 4.48% decline in Economic Operating Cash Flow (EBITDAR), which decreased from $3.71 billion to $3.54 billion over the last twelve months. The challenges of low margins in the healthcare sector, coupled with increased competition and potential disruptions in supply chains, raise concerns about Medline's ability to maintain growth and market share moving forward.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.